Could a pill curb Cocaine's high? early trial tests safety

NCT ID NCT06273540

Completed Disease control Sponsor: Stalicla SA Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested whether a drug called STP7 (mavoglurant) can safely reduce the physical and psychological effects of cocaine in 21 adults who use cocaine but are not seeking treatment. Participants received either STP7 or a placebo, then were given intravenous cocaine to monitor heart rate, blood pressure, and subjective effects. The goal was to check for dangerous interactions and see if STP7 might one day help treat cocaine use disorder.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STP7 (mavoglurant)
What this could lead to: If it works, this could point toward a treatment that helps people with cocaine use disorder by reducing the drug's rewarding effects.
What could go wrong: This is a very early Phase 1 safety study with only 21 participants, so it cannot prove effectiveness. The drug may not reduce cocaine's effects or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COCAINE USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cocaine dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COCAINE USE DISORDER

Contacts and locations

Locations

Altasciences Clinical Kansas

Overland Park, Kansas, 66212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.